Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

IMW 2019 | Using MRD as an endpoint in clinical trials

Hervé Avet-Loiseau • 14 Sep 2019
IMW 2019
Multiple Myeloma

Hervé Avet-Loiseau, MD, PhD, Cancer Research Center of Toulouse, Toulouse, France, outlines the potential benefits of using (measurable residual disease) MRD as an
an endpoint in myeloma treatment at the International Myeloma Workshop (IMW) 2019, Boston, MA.

More from Hervé Avet-Loiseau

Comparing MRD analysis methods 2:11
Comparing MRD analysis methods
Hervé Avet-Loiseau • 14 Sep 2019
Working towards a cure for multiple myeloma 14:15
Working towards a cure for multiple myeloma
Brian Walker et al. • 27 Jan 2017
Challenges and future perspectives for minimal residual disease (MRD) in multiple myeloma 11:23
Challenges and future perspectives for minimal residual disease (MRD) in multiple myeloma
Bruno Paiva et al. • 27 Jan 2017
The main prognostic factors and why minimal residual disease is becoming crucial in multiple myeloma 3:22
The main prognostic factors and why minimal residual disease is becoming crucial in multiple myeloma
Hervé Avet-Loiseau • 30 Apr 2016

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals